ReviewCancers2023
Developing Cardio-Oncology Programs in the New Era: Beyond Ventricular Dysfunction Due to Cancer Treatments.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Determining oncology nurses' awareness of cardio-oncology in Türkiye: A descriptive study.Asia-Pacific journal of oncology nursing · 2026Article
- Ischemic heart disease and cardio-onco-hematology: a comprehensive review.Cardio-oncology (London, England) · 2026Review
- Exploring healthcare professionals' experiences and perceptions of self-management of cancer therapy-induced cardiotoxicity in breast cancer survivors: a qualitative study.Cardio-oncology (London, England) · 2026Article
- Integrated Cardio-oncology Service.Cardiac failure review · 2026Review
- The role of a cardio-oncology clinical nurse specialist in the United Kingdom.Asia-Pacific journal of oncology nursing · 2025Review
- Lymphoma and Long-Term cardiovascular disease risk: A comprehensive analysis from the UK biobank.Annals of hematology · 2025Article
- Core outcome set for cardio-oncology: development of a set of outcomes for the cardiovascular assessment and monitoring of cancer patients and survivors.European heart journal. Quality of care & clinical outcomes · 2025Article
- Cardio-oncology care in Africa: current trends and disparities.Cardio-oncology (London, England) · 2025Article
- Association Between Advanced TNM Stages and Increased Risk of Cardiac Dysfunction in Patients with LVEF < 50.Medicina (Kaunas, Lithuania) · 2025Article
- Cardiotoxicity in Breast Cancer: Impact of Clinical Classifications and Treatment on Heart Health.Cancers · 2024Article
- Pericardial Disease in Patients with Cancer: Clinical Insights on Diagnosis and Treatment.Cancers · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease is a common problem in cancer patients that is becoming more widely recognized. This may be a consequence of prior cardiovascular risk factors but could also be secondary to the anticancer treatments. With the goal of offering a multidisciplinary approach to guaranteeing optimal cancer therapy and the early detection of related cardiac diseases, and in light of the recent ESC Cardio-Oncology Guideline recommendations, we developed a Cardio-Oncology unit devoted to the prevention and management of these specific complications. This document brings together important aspects to consider for the development and organization of a Cardio-Oncology program through our own experience and the current evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.